Pioglitazone inhibits connective tissue growth factor expression in advanced atherosclerotic plaques in low-density lipoprotein receptor-deficient mice

Diabetes and cardiovascular disease. The Framingham study

William B. Kannel · JAMA · 1979 · 4K citations

Medicine, Cardiology, Endocrinology +17

Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice

Andrew C. Li, Kathleen K. Brown, Mercedes Silvestre et al. · Journal of Clinical Investigation · 2000 · 841 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice.

Shun Ishibashi, Joseph L. Goldstein, Michael S. Brown et al. · Journal of Clinical Investigation · 1994 · 723 citations · Full text

Life Sciences, Cardiology, Pathobiology +17

Potent Inhibitory Effect of Troglitazone on Carotid Arterial Wall Thickness in Type 2 Diabetes

J Minamikawa, Satsuki Tanaka, Mika Yamauchi et al. · The Journal of Clinical Endocrinology & Metabolism · 1998 · 453 citations

Medicine, Endocrinology, Pharmacology +17

Troglitazone Inhibits Formation of Early Atherosclerotic Lesions in Diabetic and Nondiabetic Low Density Lipoprotein Receptor–Deficient Mice

Alan R. Collins, Woerner P. Meehan, Ulrich Kintscher et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2001 · 390 citations

Medicine, Cardiology, Pharmacology +15